CRBU · Caribou Biosciences, Inc. · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $10.04M | $11.16M | $9.99M | $34.48M | $13.85M | $9.6M | $12.36M | $5.79M | |
| $85.77M | $109.44M | $130.15M | $112.08M | $82.23M | $52.26M | $34.43M | $23.64M | |
| $33.74M | $37.91M | $46.46M | $38.46M | $38.02M | $24.32M | $14.06M | $16.46M | |
| $2.59M | $3.65M | $3.93M | $3.53M | $1.62M | $984K | $900K | $751K | |
| $119.51M | $159.5M | $176.61M | $150.54M | $120.25M | $76.58M | $48.49M | $40.09M | |
| -$109.47M | -$148.34M | -$166.62M | -$116.06M | -$106.4M | -$66.98M | -$36.12M | -$34.31M | |
| — | -1329.37% | -1667.16% | -336.63% | -768.17% | -697.84% | -292.24% | -592.69% | |
| -$106.89M | -$144.7M | -$162.69M | -$112.53M | -$104.78M | -$66M | -$35.22M | -$33.55M | |
| $4000 | — | — | — | — | $8000 | $20K | $4000 | |
| $5.52M | -$331K | $17.5M | $14.18M | $7.05M | $377K | -$3000 | $3.34M | |
| — | -$148.68M | -$149.11M | -$101.88M | -$99.35M | -$66.6M | -$36.13M | -$30.97M | |
| — | -$550K | -$9000 | $193K | $70K | $321K | -$1.82M | -$7.54M | |
| -$103.4M | -$148.13M | -$149.11M | -$102.07M | -$99.42M | -$66.92M | -$34.31M | -$23.43M | |
| — | -1327.4% | -1491.95% | -296.05% | -717.79% | -697.26% | -277.55% | -404.82% | |
| -$103.51M | -$148.28M | -$148.88M | -$100.52M | -$100.8M | -$67.06M | -$34.31M | -$23.43M | |
| USD/shares | -$1.08 | -$1.59 | -$1.65 | -$1.38 | -$1.64 | -$2.11 | — | — |
| USD/shares | -$1.08 | -$1.59 | -$1.65 | -$1.38 | -$1.64 | -$2.11 | — | — |
| shares | — | 93.39M | 90.32M | 73.81M | 60.8M | 31.66M | 8.55M | 8.37M |
| shares | — | 93.39M | 90.32M | 73.81M | 60.8M | 31.66M | 8.55M | 8.37M |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 308 similar-size Biotechnology companies (of 536 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $11,159,000 | $9,994,000 | $34,477,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| United States | $9,478,000 | $9,270,000 | $32,770,000 | $13,303,000 | $8,913,000 | $12,003,000 | $5,349,000 |
| Non Us | $1,681,000 | $724,000 | $1,707,000 | $548,000 | $685,000 | $358,000 | $439,000 |